Comorbid CAD and Ventricular Hypertrophy Compromise the Perfusion of Myocardial Tissue at Subcritical Stenosis of Epicardial Coronaries

Overview

Journal Egypt Heart J

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2019 Oct 30

PMID 31659531

Authors

Eslam Abbas

Affiliations

Soon will be listed here.

Abstract

Background: Most studies of CAD revascularization have been based on and reported according to angiographic criteria which do not consider the relation between the resulting effective flow distal to the stenosis and the demand of a hypertrophied myocardial tissue.

Results: A mathematical model of the myocardial perfusion in comorbid CAD and ventricular hypertrophy, using Poiseuille's law, indicates that the affected patients are more sensitive to CAD-related hemodynamic changes. They are more prone to develop ischemic complications, mainly non-ST-elevation myocardial infarction (NSTEMI), and arrhythmias than their peers with isolated CAD regarding the same degree of coronary stenosis.

Conclusion: Patients with comorbid CAD and ventricular hypertrophy suffer from myocardial hypoperfusion at subcritical epicardial stenosis. Accordingly, the comorbidity of both diseases should be considered upon designing of the treatment regimen.

References

Reed G, Rossi J, Cannon C . Acute myocardial infarction. Lancet. 2016; 389(10065):197-210. DOI: 10.1016/S0140-6736(16)30677-8. View

Muller J, Davis M, Chilian W . Integrated regulation of pressure and flow in the coronary microcirculation. Cardiovasc Res. 1996; 32(4):668-78. View

Arpino J, Nong Z, Li F, Yin H, Ghonaim N, Milkovich S . Four-Dimensional Microvascular Analysis Reveals That Regenerative Angiogenesis in Ischemic Muscle Produces a Flawed Microcirculation. Circ Res. 2017; 120(9):1453-1465. DOI: 10.1161/CIRCRESAHA.116.310535. View

Ghuran A, Camm A . Ischaemic heart disease presenting as arrhythmias. Br Med Bull. 2002; 59:193-210. DOI: 10.1093/bmb/59.1.193. View

. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001; 358(9286):951-7. DOI: 10.1016/S0140-6736(01)06100-1. View

Tonino P, De Bruyne B, Pijls N, Siebert U, Ikeno F, van t Veer M . Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3):213-24. DOI: 10.1056/NEJMoa0807611. View

Leach A, Fisher M . Myocardial ischaemia and cardiac pain - a mysterious relationship. Br J Pain. 2015; 7(1):23-30. PMC: 4590151. DOI: 10.1177/2049463712474648. View

Treasure C, Klein J, Vita J, Manoukian S, Renwick G, Selwyn A . Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993; 87(1):86-93. DOI: 10.1161/01.cir.87.1.86. View

Samak M, Fatullayev J, Sabashnikov A, Zeriouh M, Schmack B, Farag M . Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis. Med Sci Monit Basic Res. 2016; 22:75-9. PMC: 4976758. DOI: 10.12659/MSMBR.900437. View

10.

Millgard J, Hagg A, Kahan T, Landelius J, Malmqvist K, Sarabi M . Left ventricular hypertrophy is associated with an attenuated endothelium-dependent vasodilation in hypertensive men. Blood Press. 2001; 9(6):309-14. DOI: 10.1080/080370500300000879. View

11.

Ooi J, Bernardo B, McMullen J . The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy. Future Med Chem. 2014; 6(2):205-22. DOI: 10.4155/fmc.13.196. View

12.

Safran N, Shneyvays V, Balas N, Jacobson K, Nawrath H, Shainberg A . Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell Biochem. 2001; 217(1-2):143-52. PMC: 5574028. DOI: 10.1023/a:1007209321969. View

13.

Ellison G, Waring C, Vicinanza C, Torella D . Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms. Heart. 2011; 98(1):5-10. DOI: 10.1136/heartjnl-2011-300639. View

14.

Laughlin M . Joseph B. Wolfe Memorial lecture. Physical activity in prevention and treatment of coronary disease: the battle line is in exercise vascular cell biology. Med Sci Sports Exerc. 2004; 36(3):352-62. DOI: 10.1249/01.mss.0000117114.02875.5c. View

15.

Windecker S, Stortecky S, Stefanini G, da Costa B, daCosta B, Rutjes A . Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014; 348:g3859. PMC: 4066935. DOI: 10.1136/bmj.g3859. View

16.

Erne P, Schoenenberger A, Burckhardt D, Zuber M, Kiowski W, Buser P . Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007; 297(18):1985-91. DOI: 10.1001/jama.297.18.1985. View

17.

Levine G, Bates E, Blankenship J, Bailey S, Bittl J, Cercek B . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and.... J Am Coll Cardiol. 2011; 58(24):e44-122. DOI: 10.1016/j.jacc.2011.08.007. View

18.

Hueb W, Soares P, Gersh B, Cesar L, Luz P, Puig L . The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004; 43(10):1743-51. DOI: 10.1016/j.jacc.2003.08.065. View

19.

Libby P, Theroux P . Pathophysiology of coronary artery disease. Circulation. 2005; 111(25):3481-8. DOI: 10.1161/CIRCULATIONAHA.105.537878. View

20.

Chatterjee S, Bavishi C, Sardar P, Agarwal V, Krishnamoorthy P, Grodzicki T . Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol. 2014; 114(7):1049-52. DOI: 10.1016/j.amjcard.2014.07.015. View